Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Otago Medical School staff profiles

Professor Michelle Glass

PositionHead of Department
DepartmentDepartment of Pharmacology and Toxicology
QualificationsPhD BSc
Research summaryCannabinoids, neurodegenerative diseases, Huntington’s disease, G-protein coupled receptors

Research

Professor Michelle Glass is the Head of the Department of Pharmacology and Toxicology. The molecular pharmacologist had most recently been working at the University of Auckland for 18 years where she was Head of the Department of Pharmacology and in 2017 appointed Professor of Pharmacology.

She has now returned to the department where her working career began 23 years ago. Professor Glass’ first role after graduating with a PhD from the Department of Pharmacology at the University of Auckland in 1995 was as an Assistant Lecturer in the Department of Pharmacology at the University of Otago.

Her initial stint at Otago was brief as she took up a fellowship in the United States the following year. She worked as a postdoctoral Fellow in the Laboratory of Cellular and Molecular Regulation at the National Institute of Mental Health in Bethesda, Maryland for 18 months before moving on to work as a Visiting Fellow in the Laboratory of Cell Biology at the National Institute of Deafness and Other Communications Disorders in Rockville, Maryland. She returned to New Zealand in 2000 and took up a role as a Lecturer within the Department of Pharmacology at the University of Auckland.

Professor Glass’ research focuses on the expression, function and molecular pharmacology of the cannabinoid receptors and their potential role in treatment of neurodegenerative diseases. Her recent research interests have extended to identifying the mechanism by which synthetic cannabinoids are resulting in high levels of toxicity in the community and advising on the development of clinical trials for medicinal cannabis products.

Currently, Professor Glass is a member of the Medical Cannabis Research Collaborative (NZ), which aims to ensure robust clinical research of medical cannabis products in New Zealand is undertaken. It will also set informal standards for the development and testing of medical cannabis products, as well as increasing understanding and the base of evidence for or against the use of medical cannabis products in specific clinical conditions. Her contributions to the field have been acknowledged by an early career award from the International Cannabinoid Research Society in 2009 and by election to President of this society.

She acknowledges it is an interesting time with change potentially in the wind with so many countries legalising cannabis.

“I think it’s important that the science keeps up with the public debate.”

Read more in Otago Bulletin:
Synthetic cannabis under spotlight for new Pharmacology head

Publications

Ong, R. S., Kappatos, D. C., Russell, S. G. G., Poulsen, H. A., Banister, S. D., Gerona, R. R., Glass, M., … McCarthy, M.-J. (2019). Simultaneous analysis of 29 synthetic cannabinoids and metabolites, amphetamines and cannabinoids in human whole blood by LC-MS/MS: A New Zealand perspective of use in 2018. Drug Testing & Analysis. Advance online publication. doi: 10.1002/dta.2697

Singh, S., Oyagawa, C. R. M., Macdonald, C., Grimsey, N. L., Glass, M., & Vernall, A. J. (2019). Chromenopyrazole-based high affinity, selective fluorescent ligands for cannabinoid type 2 receptor. ACS Medicinal Chemistry Letters, 10, 209-214. doi: 10.1021/acsmedchemlett.8b00597

Kevin, R. C., Anderson, L., McGregor, I. S., Boyd, R., Manning, J. J., Glass, M., … Banister, S. D. (2019). CUMYL-4CN-BINACA is an efficacious and potent pro-convulsant synthetic cannabinoid receptor agonist. Frontiers in Pharmacology, 10, 595. doi: 10.3389/fphar.2019.00595

Banister, S. D., Adams, A., Kevin, R. C., Macdonald, C., Glass, M., Boyd, R., … Gerona, R. R. (2019). Synthesis and pharmacology of new psychoactive substance 5F‐CUMYL‐P7AICA, a scaffold-hopping analog of synthetic cannabinoid receptor agonists 5F‐CUMYL‐PICA and 5F‐CUMYL‐PINACA. Drug Testing & Analysis, 11(2), 279-291. doi: 10.1002/dta.2491

Zhu, X., Finlay, D. B., Glass, M., & Duffull, S. B. (2019). An intact model for quantifying functional selectivity. Scientific Reports, 9, 2557. doi: 10.1038/s41598-019-39000-z

Chapter in Book - Research

Ashton, J. C., Dowie, M. J., & Glass, M. (2017). The endocannabinoid system and human brain functions: Insight from memory, motor, and mood pathologies. In E. Murillo-Rodríguez (Ed.), The endocannabinoid system. (pp. 115-186). London, UK: Academic Press. doi: 10.1016/B978-0-12-809666-6.00005-8

Cawston, E. E., Hunter, M. R., & Glass, M. (2017). Allosteric modulation of the cannabinoid CB1 receptor. In V. R. Preedy (Ed.), Handbook of cannabis and related pathologies: Biology, pharmacology, diagnosis, and treatment. (pp. 573-583). London, UK: Academic Press. doi: 10.1016/B978-0-12-800756-3.00070-3

Hunter, M. R., Finlay, D. B., & Glass, M. (2017). Signal transduction and regulation of the cannabinoid CB1 receptor. In V. R. Preedy (Ed.), Handbook of cannabis and related pathologies: Biology, pharmacology, diagnosis, and treatment. (pp. 563-572). London, UK: Academic Press. doi: 10.1016/B978-0-12-800756-3.00069-7

Kho, D. T., Glass, M., & Graham, E. S. (2017). Is the cannabinoid CB2 receptor a major regulator of the neuroinflammatory axis of the neurovascular unit in humans? In D. Kendall & S. P. H. Alexander (Eds.), Advances in Pharmacology [Vol. 80: Cannabinoid pharmacology]. (pp. 207-221). Cambridge, MA: Academic Press. doi: 10.1016/bs.apha.2017.03.005

Hunter, M. R., Finlay, D. B., Macdonald, C. E., Cawston, E. E., Grimsey, N. L., & Glass, M. (2017). Real-time measurement of cannabinoid receptor-mediated cAMP signaling. In P. H. Reggio (Ed.), Methods in enzymology: Cannabinoids and their receptors (Vol. 593). (pp. 43-59). Cambridge, MA: Academic Press. doi: 10.1016/bs.mie.2017.05.001

Priestley, R., Glass, M., & Kendall, D. (2017). Functional selectivity at cannabinoid receptors. In D. Kendall & S. P. H. Alexander (Eds.), Advances in Pharmacology [Vol. 80: Cannabinoid pharmacology]. (pp. 207-221). Cambridge, MA: Academic Press. doi: 10.1016/bs.apha.2017.03.005

Goodfellow, C. E., & Glass, M. (2009). Anandamide receptor signal transduction. In G. Litwack (Ed.), Vitamins and hormones. (pp. 79-110). London, UK: Academic Press. doi: 10.1016/S0083-6729(09)81004-2

Ashton, J. C., & Glass, M. (2008). Multiple roles for cannabinoids in neuroprotection during oxidative stress injury. In O. M. Roux (Ed.), Brain hypoxia-ischemia research progress. (pp. 229-244). New York: Nova.

^ Top of page

Journal - Research Article

Ong, R. S., Kappatos, D. C., Russell, S. G. G., Poulsen, H. A., Banister, S. D., Gerona, R. R., Glass, M., … McCarthy, M.-J. (2019). Simultaneous analysis of 29 synthetic cannabinoids and metabolites, amphetamines and cannabinoids in human whole blood by LC-MS/MS: A New Zealand perspective of use in 2018. Drug Testing & Analysis. Advance online publication. doi: 10.1002/dta.2697

Zhu, X., Finlay, D. B., Glass, M., & Duffull, S. B. (2019). An intact model for quantifying functional selectivity. Scientific Reports, 9, 2557. doi: 10.1038/s41598-019-39000-z

Banister, S. D., Adams, A., Kevin, R. C., Macdonald, C., Glass, M., Boyd, R., … Gerona, R. R. (2019). Synthesis and pharmacology of new psychoactive substance 5F‐CUMYL‐P7AICA, a scaffold-hopping analog of synthetic cannabinoid receptor agonists 5F‐CUMYL‐PICA and 5F‐CUMYL‐PINACA. Drug Testing & Analysis, 11(2), 279-291. doi: 10.1002/dta.2491

Kevin, R. C., Anderson, L., McGregor, I. S., Boyd, R., Manning, J. J., Glass, M., … Banister, S. D. (2019). CUMYL-4CN-BINACA is an efficacious and potent pro-convulsant synthetic cannabinoid receptor agonist. Frontiers in Pharmacology, 10, 595. doi: 10.3389/fphar.2019.00595

Singh, S., Oyagawa, C. R. M., Macdonald, C., Grimsey, N. L., Glass, M., & Vernall, A. J. (2019). Chromenopyrazole-based high affinity, selective fluorescent ligands for cannabinoid type 2 receptor. ACS Medicinal Chemistry Letters, 10, 209-214. doi: 10.1021/acsmedchemlett.8b00597

Ibsen, M. S., Finlay, D. B., Patel, M., Javtich, J. A., Glass, M., & Grimsey, N. L. (2019). Cannabinoid CB1 and CB2 receptor-mediated arrestin translocation: Species, subtype, and agonist-dependence. Frontiers in Pharmacology, 10, 350. doi: 10.3389/fphar.2019.00350

Zhu, X., Finlay, D. B., Glass, M., & Duffull, S. B. (2019). Model-free and kinetic modelling approaches for characterising non-equilibrium pharmacological pathway activity: CB1 cannabinoid receptor internalisation. British Journal of Pharmacology. Advance online publication. doi: 10.1111/bph.14684

Wiley, J. L., Lefever, T. W., Glass, M., & Thomas, B. F. (2019). Do you feel it now? Route of administration and Δ9-tetrahydrocannabinol-like discriminative stimulus effects of synthetic cannabinoids in mice. NeuroToxicology, 73, 161-167. doi: 10.1016/j.neuro.2019.04.002

Oyagawa, C. R. M., de la Harpe, S. M., Saroz, Y., Glass, M., Vernall, A. J., & Grimsey, N. L. (2018). Cannabinoid Receptor 2 signalling bias elicited by 2,4,6-trisubstituted 1,3,5-triazines. Frontiers in Pharmacology, 9, 1202. doi: 10.3389/fphar.2018.01202

Cooper, A. G., Oyagawa, C. R. M., Manning, J. J., Singh, S., Hook, S., Grimsey, N. L., Glass, M., Tyndall, J. D. A., & Vernall, A. J. (2018). Development of selective, fluorescent cannabinoid type 2 receptor ligands based on a 1,8-naphthyridin-2-(1H)-one-3-carboxamide scaffold. MedChemComm, 9(12), 2055-2067. doi: 10.1039/c8md00448j

Cooper, A. G., MacDonald, C., Glass, M., Hook, S., Tyndall, J. D. A., & Vernall, A. J. (2018). Alkyl indole-based cannabinoid type 2 receptor tools: Exploration of linker and fluorophore attachment. European Journal of Medicinal Chemistry, 145, 770-789. doi: 10.1016/j.ejmech.2017.11.076

Hosie, S., Malone, D. T., Liu, S., Glass, M., Adlard, P. A., Hannan, A. J., & Hill-Yardin, E. L. (2018). Altered amygdala excitation and CB1 receptor modulation of aggressive behavior in the neuroligin-3 R451C mouse model of autism. Frontiers in Cellular Neuroscience, 12, 234. doi: 10.3389/fncel.2018.00234

Zhu, X., Finlay, D. B., Glass, M., & Duffull, S. B. (2018). An evaluation of the operational model when applied to quantify functional selectivity. British Journal of Pharmacology, 175, 1654-1668. doi: 10.1111/bph.14171

Finlay, D. B., Cawston, E. E., Grimsey, N. L., Hunter, M. R., Korde, A., Vemuri, V. K., … Glass, M. (2017). Gαs signalling of the CB1 receptor and the influence of receptor number. British Journal of Pharmacology, 174(15), 2545-2562. doi: 10.1111/bph.13866

Soethoudt, M., Grether, U., Fingerle, J., Grim, T. W., Fezza, F., de Petrocellis, L., … Finlay, D., … Glass, M., & van der Stelt, M. (2017). Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity. Nature Communications, 8, 13958. doi: 10.1038/ncomms13958

Hunter, M. R., Grimsey, N. L., & Glass, M. (2016). Sulfation of the FLAG epitope is affected by co-expression of G protein-coupled receptors in a mammalian cell model. Scientific Reports, 6, 27316. doi: 10.1038/srep27316

Banister, S. D., Longworth, M., Kevin, R., Sachdev, S., Santiago, M., Stuart, J., … Glass, M., … Kassiou, M. (2016). Pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues. ACS Chemical Neuroscience, 7(9), 1241-1254. doi: 10.1021/acschemneuro.6b00137

Finlay, D. B., Joseph, W. R., Grimsey, N. L., & Glass, M. (2016). GPR18 undergoes a high degree of constitutive trafficking but is unresponsive to N-arachidonoyl glycine. PeerJ, 2016(4), e1835. doi: 10.7717/peerj.1835

Longworth, M., Banister, S. D., Mack, J. B. C., Glass, M., Connor, M., & Kassiou, M. (2016). The 2-alkyl-2H-indazole regioisomers of synthetic cannabinoids AB-CHMINACA, AB-FUBINACA, AB-PINACA, and 5F-AB-PINACA are possible manufacturing impurities with cannabimimetic activities. Forensic Toxicology, 34(2), 286-303. doi: 10.1007/s11419-016-0316-y

Redmond, W. J., Cawston, E. E., Grimsey, N. L., Stuart, J., Edington, A. R., Glass, M., & Connor, M. (2016). Identification of N‐arachidonoyl dopamine as a highly biased ligand at cannabinoid CB1 receptors. British Journal of Pharmacology, 173(1), 115-127. doi: 10.1111/bph.13341

Cawston, E. E., Connor, M., Di Marzo, V., Silvestri, R., & Glass, M. (2015). Distinct temporal fingerprint for cyclic adenosine monophosphate (cAMP) signaling of indole-2-carboxamides as allosteric modulators of the cannabinoid receptors. Journal of Medicinal Chemistry, 58(15), 5979-5988. doi: 10.1021/acs.jmedchem.5b00579

Banister, S. D., Stuart, J., Kevin, R. C., Edington, A., Longworth, M., Wilkinson, S. M., … Glass, M., … Kassiou, M. (2015). Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chemical Neuroscience, 6(8), 1445-1458. doi: 10.1021/acschemneuro.5b00107

Khajehali, E., Malone, D. T., Glass, M., Sexton, P. M., & Christopoulos, A. (2015). Biased agonism and biased allosteric modulation at the CB1 cannabinoid receptor. Molecular Pharmacology, 88(2), 368-379. doi: 10.1124/mol.115.099192

Banister, S. D., Stuart, J., Conroy, T., Longworth, M., Manohar, M., Beinat, C., … Glass, M., … Kassiou, M. (2015). Structure–activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues. Forensic Toxicology, 33(2), 355-366. doi: 10.1007/s11419-015-0282-9

Banister, S. D., Moir, M., Stuart, J., Kevin, R. C., Wood, K. E., Longworth, M., … Glass, M., … Kassiou, M. (2015). Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chemical Neuroscience, 6(9), 1546-1559. doi: 10.1021/acschemneuro.5b00112

Young, D., Fong, D. M., Lawlor, P. A., Wu, A., Mouravlev, A., McRae, M., Glass, M., … During, M. J. (2014). Adenosine kinase, glutamine synthetase and EAAT2 as gene therapy targets for temporal lobe epilepsy. Gene Therapy, 21(12), 1029-1040. doi: 10.1038/gt.2014.82

Dowie, M. J., Grimsey, N. L., Hoffman, T., Faull, R. L. M., & Glass, M. (2014). Cannabinoid receptor CB2 is expressed on vascular cells, but not astroglial cells in the post-mortem human Huntington's disease brain. Journal of Chemical Neuroanatomy, 59-60, 62-71. doi: 10.1016/j.jchemneu.2014.06.004

MacDonald, C., Finlay, D. B., Jabed, A., Glass, M., & Graham, E. S. (2014). Development of positive control tissue for in situ hybridisation using Alvetex scaffolds. Journal of Neuroscience Methods, 238, 70-77. doi: 10.1016/j.jneumeth.2014.09.006

Yee, A. G., Lee, S.-M., Hunter, M. R., Glass, M., Freestone, P. S., & Lipski, J. (2014). Effects of the Parkinsonian toxin MPP+ on electrophysiological properties of nigral dopaminergic neurons. NeuroToxicology, 45, 1-11. doi: 10.1016/j.neuro.2014.08.009

Graham, E. S., Woo, K. K., Aalderink, M., Fry, S., Greenwood, J. M., Glass, M., & Dragunow, M. (2013). M1 muscarinic receptor activation mediates cell death in M1-HEK293 cells. PLoS ONE, 8(9), e72011. doi: 10.1371/journal.pone.0072011

Banister, S. D., Wilkinson, S. M., Longworth, M., Stuart, J., Apetz, N., English, K., … Glass, M., … Kassiou, M. (2013). The synthesis and pharmacological evaluation of adamantane-derived indoles: Cannabimimetic drugs of abuse. ACS Chemical Neuroscience, 4(7), 1081-1092. doi: 10.1021/cn400035r

Cawston, E. E., Redmond, W. J., Breen, C. M., Grimsey, N. L., Connor, M., & Glass, M. (2013). Real-time characterization of cannabinoid receptor 1 (CB1) allosteric modulators reveals novel mechanism of action. British Journal of Pharmacology, 170(4), 893-907. doi: 10.1111/bph.12329

Grimsey, N. L., Moodley, K. S., Glass, M., & Graham, E. S. (2012). Sensitive and accurate quantification of human leukocyte migration using high-content discovery-1 imaging system and ATPlite assay. Journal of Biomolecular Screening, 17(3), 386-393. doi: 10.1177/1087057111428985

Horváth, B., Magid, L., Mukhopadhyay, P., Bátkai, S., Rajesh, M., Park, O., … Glass, M., … Pacher, P. (2012). A new cannabinoid CB2 receptor agonist HU-910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury. British Journal of Pharmacology, 165(8), 2462-2478. doi: 10.1111/j.1476-5381.2011.01381.x

Goodfellow, C. E., Graham, S. E., Dragunow, M., & Glass, M. (2011). Characterization of NTera2/D1 cells as a model system for the investigation of cannabinoid function in human neurons and astrocytes. Journal of Neuroscience Research, 89(10), 1685-1697. doi: 10.1002/jnr.22692

Moodley, K., Angel, C. E., & Glass, M. (2011). Real-time profiling of NK cell killing of human astrocytes using xCELLigence technology. Journal of Neuroscience Methods, 200(2), 173-180. doi: 10.1016/j.jneumeth.2011.07.005

Grimsey, N. L., Goodfellow, C. E., Dragunow, M., & Glass, M. (2011). Cannabinoid receptor 2 undergoes Rab5-mediated internalization and recycles via a Rab11-dependent pathway. Biochimica et Biophysica Acta: Molecular Cell Reserch, 1813(8), 1554-1560. doi: 10.1016/j.bbamcr.2011.05.010

Grimsey, N. L., Graham, E. S., Dragunow, M., & Glass, M. (2010). Cannabinoid Receptor 1 trafficking and the role of the intracellular pool: Implications for therapeutics. Biochemical Pharmacology, 80(7), 1050-1062. doi: 10.1016/j.bcp.2010.06.007

Dowie, M. J., Howard, M. L., Nicholson, L. F. B., Faull, R. L. M., Hannan, A. J., & Glass, M. (2010). Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice. Neuroscience, 170(1), 324-336. doi: 10.1016/j.neuroscience.2010.06.056

Dowie, M. J., Scotter, E. L., Molinari, E., & Glass, M. (2010). The therapeutic potential of G-protein coupled receptors in Huntington's disease. Pharmacology & Therapeutics, 128(2), 305-323. doi: 10.1016/j.pharmthera.2010.07.008

Scotter, E. L., Goodfellow, C. E., Graham, E. S., Dragunow, M., & Glass, M. (2010). Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease. British Journal of Pharmacology, 160(3), 747-761. doi: 10.1111/j.1476-5381.2010.00773.x

Graham, E. S., Angel, C. E., Schwarcz, L. E., Dunbar, P. R., & Glass, M. (2010). Detailed characterisation of CB2 receptor protein expression in peripheral blood immune cells from healthy human volunteers using flow cytometry. International Journal of Immunopathology & Pharmacology, 23(1), 25-34. doi: 10.1177/039463201002300103

Scotter, E. L., Abood, M. E., & Glass, M. (2010). The endocannabinoid system as a target for the treatment of neurodegenerative disease. British Journal of Pharmacology, 160(3), 480-498. doi: 10.1111/j.1476-5381.2010.00735.x

Graham, E. S., Ashton, J. C., & Glass, M. (2009). Cannabinoid receptors: A brief history and 'What's hot'. Frontiers in Bioscience, 14, 944-957. doi: 10.2741/3288

Allen, K. L., Waldvogel, H. J., Glass, M., & Faull, R. L. M. (2009). Cannabinoid (CB1), GABAA and GABAB receptor subunit changes in the globus pallidus in Huntington's disease. Journal of Chemical Neuroanatomy, 37(4), 266-281. doi: 10.1016/j.jchemneu.2009.02.001

Dowie, M. J., Bradshaw, H. B., Howard, M. L., Nicholson, L. F. B., Faull, R. L. M., Hannan, A. J., & Glass, M. (2009). Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease. Neuroscience, 163(1), 456-465. doi: 10.1016/j.neuroscience.2009.06.014

Mitchell, M. D., Sato, T. A., Wang, A., Keelan, J. A., Ponnampalam, A. P., & Glass, M. (2008). Cannabinoids stimulate prostaglandin production by human gestational tissues through a tissue- and CB1-receptor-specific mechanism. American Journal of Physiology: Endocrinology & Metabolism, 294(2), E352-E356. doi: 10.1152/ajpendo.00495.2007

Grimsey, N. L., Goodfellow, C. E., Scotter, E. L., Dowie, M. J., Glass, M., & Graham, E. S. (2008). Specific detection of CB1 receptors: Cannabinoid CB1 receptor antibodies are not all created equal! Journal of Neuroscience Methods, 171(1), 78-86. doi: 10.1016/j.jneumeth.2008.02.014

Scotter, E. L., Narayan, P. J., Glass, M., & Dragunow, M. (2008). High throughput quantification of mutant huntingtin aggregates. Journal of Neuroscience Methods, 171(1), 174-179. doi: 10.1016/j.jneumeth.2008.02.007

Chamley, L. W., Bhalla, A., Stone, P. R., Liddell, H., O’Carroll, S., Kearn, C., & Glass, M. (2008). Nuclear localisation of the endocannabinoid metabolizing enzyme fatty acid amide hydrolase (FAAH) in invasive trophoblasts and an association with recurrent miscarriage. Placenta, 29(11), 970-975. doi: 10.1016/j.placenta.2008.08.003

McPartland, J. M., Glass, M., Matias, I., Norris, R. W., & Kilpatrick, C. W. (2007). A shifted repertoire of endocannabinoid genes in the zebrafish (Danio rerio). Molecular Genetics & Genomics, 277(5), 555-570. doi: 10.1007/s00438-007-0207-3

Ashton, J. C., & Glass, M. (2007). The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Current Neuropharmacology, 5(2), 73-80.

Ashton, J. C., Rahman, R. M. A., Nair, S. M., Sutherland, B. A., Glass, M., & Appleton, I. (2007). Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neuroscience Letters, 412, 114-117.

McPartland, J. M., Glass, M., & Pertwee, R. B. (2007). Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: Interspecies differences. British Journal of Pharmacology, 152(5), 583-593. doi: 10.1038/sj.bjp.0707399

Saidak, Z., Blake-Palmer, K., Hay, D. L., Northup, J. K., & Glass, M. (2006). Differential activation of G-proteins by μ-opioid receptor agonists. British Journal of Pharmacology, 147(6), 671-680. doi: 10.1038/sj.bjp.0706661

Curtis, M. A., Faull, R. L. M., & Glass, M. (2006). A novel population of progenitor cells expressing cannabinoid receptors in the subependymal layer of the adult normal and Huntington's disease human brain. Journal of Chemical Neuroanatomy, 31(3), 210-215. doi: 10.1016/j.jchemneu.2006.01.005

Graham, E. S., Ball, N., Scotter, E. L., Narayan, P., Dragunow, M., & Glass, M. (2006). Induction of Krox-24 by endogenous cannabinoid type 1 receptors in Neuro2a cells is mediated by the MEK-ERK MAPK pathway and is suppressed by the phosphatidylinositol 3-kinase pathway. Journal of Biological Chemistry, 281(39), 29085-29095. doi: 10.1074/jbc.M602516200

McPartland, J. M., Agraval, J., Gleeson, D., Heasman, K., & Glass, M. (2006). Cannabinoid receptors in invertebrates. Journal of Evolutionary Biology, 19(2), 366-373. doi: 10.1111/j.1420-9101.2005.01028.x

McPartland, J. M., Matias, I., Di Marzo, V., & Glass, M. (2006). Evolutionary origins of the endocannabinoid system. Gene, 370(1-2), 64-74. doi: 10.1016/j.gene.2005.11.004

Kearn, C. S., Blake-Palmer, K., Daniel, E., Mackie, K., & Glass, M. (2005). Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: A mechanism for receptor cross-talk? Molecular Pharmacology, 67(5), 1697-1704. doi: 10.1124/mol.104.006882

Park, B., McPartland, J. M., & Glass, M. (2004). Cannabis, cannabinoids and reproduction. Prostaglandins, Leukotrienes & Essential Fatty Acids, 70(2), 189-197. doi: 10.1016/j.plefa.2003.04.007

Glass, M., van Dellen, A., Blakemore, C., Hannan, A. J., & Faull, R. L. M. (2004). Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors. Neuroscience, 123(1), 207-212. doi: 10.1016/S0306-4522(03)00595-5

Helliwell, R. J. A., Chamley, L. W., Blake-Palmer, K., Mitchell, M. D., Wu, J., Kearn, C. S., & Glass, M. (2004). Characterization of the endocannabinoid system in early human pregnancy. Journal of Clinical Endocrinology & Metabolism, 89(10), 5168-5174. doi: 10.1210/jc.2004-0388

Park, B., Gibbons, H. M., Mitchell, M. D., & Glass, M. (2003). Identification of the CB1 cannabinoid receptor and fatty acid amide hydrolase (FAAH) in the human placenta. Placenta, 24(10), 990-995. doi: 10.1016/S0143-4004(03)00165-6

McPartland, J. M., & Glass, M. (2003). Functional mapping of cannabinoid receptor homologs in mammals, other vertebrates, and invertebrates. Gene, 312(1-2), 297-303. doi: 10.1016/S0378-1119(03)00638-3

McAllister, S. D., & Glass, M. (2002). CB1 and CB2 receptor-mediated signalling: A focus on endocannabinoids. Prostaglandins, Leukotrienes & Essential Fatty Acids, 66(2-3), 161-171. doi: 10.1054/plef.2001.0344

McPartland, J., Di Marzo, V., De Petrocellis, L., Mercer, A., & Glass, M. (2001). Cannabinoid receptors are absent in insects. Journal of Comparative Neurology, 436(4), 423-429. doi: 10.1002/cne.1078

Glass, M. (2001). The role of cannabinoids in neurodegenerative diseases. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 25(4), 743-765. doi: 10.1016/S0278-5846(01)00162-2

McPartland, J., Di Marzo, V., De Petrocellis, L., Mercer, A. R., & Glass, M. (2001). Cannabinoid receptors absent in insects. Journal of Comparative Neurology, 436, 423-429.

Buckley, N. E., McCoy, K. L., Mezey, É., Bonner, T., Zimmer, A., Felder, C. C., & Glass, M. (2000). Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor. European Journal of Pharmacology, 396(2-3), 141-149. doi: 10.1016/S0014-2999(00)00211-9

Glass, M., Dragunow, M., & Faull, R. L. M. (2000). The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience, 97(3), 505-519. doi: 10.1016/S0306-4522(00)00008-7

Glass, M., & Northup, J. K. (1999). Agonist selective regulation of G proteins by cannabinoid CB1 and CB2 receptors. Molecular Pharmacology, 56(6), 1362-1369. doi: 10.1124/mol.56.6.1362

Felder, C. C., Joyce, K. E., Briley, E. M., Glass, M., Mackie, K. P., Fahey, K. J., … Brownstein, M. (1998). LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. Journal of Pharmacology & Drug Metabolism, 284(1), 291-297.

Felder, C. C., & Glass, M. (1998). Cannabinoid receptors and their endogenous agonists. Annual Review of Pharmacology & Toxicology, 38, 179-200.

Glass, M., & Felder, C. C. (1997). Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: Evidence for a Gs linkage to the CB1 receptor. Journal of Neuroscience, 17(14), 5327-5333. doi: 10.1523/JNEUROSCI.17-14-05327.1997

Glass, M., Dragunow, M., & Faull, R. L. M. (1997). Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 77(2), 299-318. doi: 10.1016/S0306-4522(96)00428-9

Glass, M., Faull, R. L. M., Bullock, J. Y., Jansen, K., Mee, E. W., Walker, E. B., … Dragunow, M. (1996). Loss of A1 adenosine receptors in human temporal lobe epilepsy. Brain Research, 710(1-2), 56-68. doi: 10.1016/0006-8993(95)01313-X

Glass, M., & Dragunow, M. (1995). Induction of the Krox 24 transcription factor in striosomes by a cannabinoid agonist. NeuroReport, 6(2), 241-244.

Glass, M., & Dragunow, M. (1995). Neurochemical and morphological changes associated with human epilepsy. Brain Research Reviews, 21(1), 29-41. doi: 10.1016/0165-0173(95)00005-N

Dragunow, M., Tse, C., Glass, M., & Lawlor, P. (1994). c-fos antisense reduces expression of Krox 24 in rat caudate and neocortex. Cellular & Molecular Neurobiology, 14(5), 395-405.

Glass, M., Faull, R. L. M., & Dragunow, M. (1993). Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience, 56(3), 523-527. doi: 10.1016/0306-4522(93)90352-G

Glass, M., Faull, R. L. M., & Dragunow, M. (1993). Localisation of the adenosine uptake site in the human brain: A comparison with the distribution of adenosine A1 receptors. Brain Research, 710(1-2), 79-91. doi: 10.1016/0006-8993(95)01318-0

^ Top of page

Journal - Research Other

Banister, S. D., Arnold, J. C., Connor, M., Glass, M., & McGregor, I. S. (2019). Dark classics in chemical neuroscience: Δ9-tetrahydrocannabinol. ACS Chemical Neuroscience. Advance online publication. doi: 10.1021/acschemneuro.8b00651

Glass, M., & Ashton, J. C. (2019). What is medicinal cannabis? New Zealand Medical Journal, 132(1494), 49-56. Retrieved from https://www.nzma.org.nz/journal

Glass, M., Govindpani, K., Furkert, D. P., Hurst, D. P., Reggio, P. H., & Flanagan, J. U. (2016). One for the price of two: Are bivalent ligands targeting cannabinoid receptor dimers capable of simultaneously binding to both receptors? Trends in Pharmacological Sciences, 37(5), 353-363. doi: 10.1016/j.tips.2016.01.010

Hunter, M. R., & Glass, M. (2015). Increasing the flexibility of the LANCE cAMP detection kit [Brief communication]. Journal of Pharmacological & Toxicological Methods, 71, 42-45. doi: 10.1016/j.vascn.2014.10.008

Glass, M., Hong, J., Sato, T. A., & Mitchell, M. D. (2005). Misidentification of prostamides as prostaglandins [Rapid communication]. Journal of Lipid Research, 46(7), 1364-1368. doi: 10.1194/jlr.C500006-JLR200

McPartland, J. M., & Glass, M. (2001). Nematicidal effects of hemp (Cannabis sativa) may not be mediated by cannabinoid receptors. New Zealand Journal of Crop & Horticultural Science, 29(4), 301-307. doi: 10.1080/01140671.2001.9514191

Glass, M., Brotchie, J. M., & Maneuf, Y. P. (1997). Modulation of neurotransmission by cannabinoids in the basal ganglia. European Journal of Neuroscience, 9(2), 199-203. doi: 10.1111/j.1460-9568.1997.tb01390.x

More publications...